Loading clinical trials...

Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT | Clinical Trials | Clareo Health

RECRUITING

Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT

The Safety and Efficiency of Beijing Protocol in Malignant Hematologic Disease Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT

NCT05921318•Peking University People's Hospital

View on ClinicalTrials.gov

Summary

The aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 5/10 HLA-mismatched allo-HSCT.

Detailed Description

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative procedure for patients with hematological malignancies.Donor-recipient human leukocyte antigen (HLA) compatibility plays a key role in successful allo-HSCT as HLA-matching has a direct impact on the risk of GvHD, non-relapse mortality (NRM), and survival. Suitable, matched or haploidentical donors are not always available or accessible, even in the era of the international registries.Therefore, there is a need for new strategies that could negate the barrier of HLA-mismatching, allowing allo-HSCT from traditionally prohibitive highly mismatched donors.The aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 5/10 HLA-mismatched allo-HSCT.

Eligibility

Age

0 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•hematologic malignancy patients
•patients eligible for the transplantation of allogeneic hematopoietic stem cells;
•patients unavailable with HLA matched donor or related haploidentical donor
•voluntary participation in this study and signing the informed consent form.

Exclusion Criteria

•Patients with the severe infections;
•Pregnant or lactating women
•Patients who are enrolled in other clinical trials within 1 month;
•Patients who may not be able to complete the study for other reasons, or may be considered by the investigator not suitable to participate in the study;
•Patients unable to properly understand or refusing to accept the informed consent form.

Locations (1)

Deparment of Hematology, Peking University People's Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

June 1, 2023

Primary Completion Date

May 31, 2024

Completion Date

May 31, 2026

Last Updated

June 27, 2023

Enrollment

ESTIMATED participants

Conditions

Hematologic MalignancyStem Cell Transplant Complications

Interventions

Beijing protocol

COMBINATION_PRODUCT

Contacts

Yu Wang, Prof.

CONTACT

13552647384 ywyw3172@sina.com

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

Mantle Cell LymphomaNon Hodgkin Lymphoma+1 more

View study

RECRUITINGPHASE1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

NCT07257419

Relapsed Pediatric ALLHematopoietic Cell Transplantation+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 27, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT

Inclusion Criteria

Exclusion Criteria

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)